Goldman Sachs
AVNR

Goldman Sachs’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Goldman Sachs’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-337,576
Closed -$5.72M – 7581
2014
Q4 		$5.72M Sell
337,576
-542,609
-62% -$7.63M ﹤0.01% 2872
2014
Q3 		$10.5M Buy
880,185
+136,030
+18% +$929K ﹤0.01% 2321
2014
Q2 		$4.2M Sell
744,155
-809,527
-52% -$3.73M ﹤0.01% 3238
2014
Q1 		$5.7M Buy
1,553,682
+468,541
+43% +$1.79M ﹤0.01% 2877
2013
Q4 		$3.65M Buy
1,085,141
+971,560
+855% +$4.01M ﹤0.01% 3441
2013
Q3 		$480K Buy
113,581
+64,905
+133% +$308K ﹤0.01% 5184
2013
Q2 		$224K Buy
+48,676
New +$167K ﹤0.01% 5513

Goldman Sachs's AVNR Position: Q1 2015 in Review

Goldman Sachs sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 337,576 shares — an estimated $5.72M sold.

Goldman Sachs first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $10.5M in Q3 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • Goldman Sachs reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • Goldman Sachs sold 337,576 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $5.72M.
  • Goldman Sachs first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
  • Goldman Sachs's AVANIR PHARMACEUTICALS, INC CL A position peaked at $10.5M in Q3 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Goldman Sachs's 13F filing for Q1 2015, filed 15 May 2015.